News & Updates

Gestational diabetes linked to altered gut microbiome and larger head circumference in male offspring
Gestational diabetes linked to altered gut microbiome and larger head circumference in male offspring
28 Aug 2024 byKanas Chan

Gestational diabetes mellitus (GDM) not only disrupts the gut microbiome of mothers and their infants, but is also linked to increased head circumference in male offspring, researchers from the Chinese University of Hong Kong (CUHK) have shown.

Gestational diabetes linked to altered gut microbiome and larger head circumference in male offspring
28 Aug 2024
Preterm preeclampsia screen-and-prevent strategy to launch across HK’s public hospitals after initial success
Preterm preeclampsia screen-and-prevent strategy to launch across HK’s public hospitals after initial success
27 Aug 2024 byChristina Lau

A screen-and-prevent strategy for preterm preeclampsia (PE), which involves screening in the first trimester and low-dose aspirin prophylaxis for high-risk women in <16–36 weeks of gestation, will be launched in obstetric units of public hospitals across Hong Kong following promising results from a multicentre Asian trial led by the Chinese University of Hong Kong (CUHK) and a pilot programme at the Prince of Wales Hospital (PWH).

Preterm preeclampsia screen-and-prevent strategy to launch across HK’s public hospitals after initial success
27 Aug 2024
Cervical cancer: PFS advantage with pembrolizumab plus CCRT consistent in Asians
Cervical cancer: PFS advantage with pembrolizumab plus CCRT consistent in Asians
21 Aug 2024 byJairia Dela Cruz

Patients with high-risk locally advanced cervical cancer in East Asia get progression-free survival (PFS) boost with pembrolizumab plus concurrent chemoradiotherapy (CCRT), similar to those observed in the overall population of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.

Cervical cancer: PFS advantage with pembrolizumab plus CCRT consistent in Asians
21 Aug 2024
Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
20 Aug 2024 byStephen Padilla

Treatment with rucaparib in patients with newly diagnosed advanced ovarian cancer provides long-term improvements in progression-free survival (PFS) both in those with high and low risk of disease progression, as shown in the updated PFS analyses of the ATHENA-MONO study.

Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
20 Aug 2024